A llama-derived nanobody targeting h3 protein of monkeypox virus, a detection reagent comprising the same and application thereof
By screening and measuring the high affinity of alpaca-derived nanobodies H3S1G1-mFc, the problem of insufficient affinity of monkeypox virus H3 antigen nanobodies in existing technologies has been solved, achieving efficient prevention, treatment and detection of monkeypox virus.
Patent Information
- Application Number
- CN202610483385.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-13
- Publication Date
- 2026-07-17
AI Technical Summary
The lack of high-affinity monkeypox virus H3 antigen nanobodies in existing technologies, coupled with the unverified effectiveness of existing drugs against monkeypox virus, leads to an increased risk of infection among young and middle-aged adults. There is also a lack of vaccines and drugs with independent intellectual property rights.
By screening alpaca-derived nanobody libraries, high-affinity H3S1G1-mFc nanobodies were obtained. These nanobodies were then bound to monkeypox virus H3 antigen, and their affinity was determined using phage display and surface plasmon resonance techniques. This led to the development of nanobodies for the treatment, diagnosis, and prevention of monkeypox virus infection.
We have developed a high-affinity and high-sensitivity nanobody, H3S1G1-mFc, for the clinical prevention, treatment, and detection of monkeypox virus, which enhances the inhibitory effect on viral infection.
Smart Images
Figure CN122404538A_ABST
Abstract
Citation Information
Patent Citations
Antibodies against monkeypox virus h3 protein and methods of making the same
CN120137012B
RNA containing modified nucleosides and methods of use thereof
US8278036B2